Supernus Pharmaceuticals Inc
$ 47.64
1.88%
07 Aug - close price
- Market Cap 2,771,123,000 USD
- Current Price $ 47.64
- High / Low $ 47.88 / 46.43
- Stock P/E N/A
- Book Value 17.73
- EPS -1.92
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE -0.10 %
- 52 Week High 59.68
- 52 Week Low 40.32
About
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$62.50
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-03 | 2026-05-05 | 2026-02-24 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-25 | 2024-11-04 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-08 |
| Reported EPS | 0.39 | 0.21 | 0.8821 | 0.61 | 0.91 | 0.44 | 0.5483 | 1.1 | 0.67 | 0.24 | 0.89 | 0.24 |
| Estimated EPS | 0.3 | 0.28 | 0.41 | 0.82 | 0.47 | 0.37 | 0.52 | 0.44 | 0.39 | 0.38 | 0.55 | 0.08 |
| Surprise | 0.09 | -0.07 | 0.4721 | -0.21 | 0.44 | 0.07 | 0.0283 | 0.66 | 0.28 | -0.14 | 0.34 | 0.16 |
| Surprise Percentage | 30% | -25% | 115.1463% | -25.6098% | 93.617% | 18.9189% | 5.4423% | 150% | 71.7949% | -36.8421% | 61.8182% | 200% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SUPN
2026-08-06 10:09:54
Supernus Pharmaceuticals, Inc. announced positive earnings pre-announcements, updating its fiscal year 2026 revenue range from $840-$870 Million to $860-$890 Million. The company has been active in mergers and acquisitions, including a proposed merger with Indivior and an acquisition of Sage Therapeutics, and has seen various FDA approvals and clinical trial developments for its treatments.
2026-08-05 12:46:04
Supernus Pharmaceuticals, Inc. has pre-announced positive earnings, revising its fiscal year 2026 revenue guidance from an estimated $840-$870 million to $860-$890 million. This update highlights the company's financial performance and future projections. The article also provides a list of recent news related to Supernus, including mergers, quarterly results, and FDA approvals.
2026-08-04 12:57:00
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a diversified biopharmaceutical company focused on the central nervous system (CNS). The combined entity, which will operate under the name Supernus Inc. and trade on Nasdaq under 'SUPN', expects pro forma net revenue of $2.2 billion and $125 million in annual cost synergies. The merger will create a portfolio of 11 medicines for neurology, addiction, and psychiatry, with current Supernus CEO Jack Khattar leading the new company.
2026-08-04 01:39:40
Monteverde & Associates PC, a class action firm, has announced an investigation into Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) concerning its proposed sale to Indivior Pharmaceuticals, Inc. The firm is examining whether the deal, where Supernus shareholders would receive 1.5401 common shares of Indivior for each Supernus share, is fair to shareholders. Shareholders are encouraged to contact the firm for more information about the investigation.
2026-08-04 00:39:40
Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. announced a definitive agreement to merge in an all-stock, tax-free transaction, creating a U.S. biopharmaceutical company focused on central nervous system (CNS) diseases. The combined entity will be headquartered in Rockville, Maryland, with Supernus CEO Jack A. Khattar serving as CEO. The merger aims to build a diversified platform with established commercial franchises, pipeline, R&D capabilities, and a strong financial profile, with closing expected in Q4 2026.
2026-08-03 20:45:00
Supernus Pharmaceuticals is set to report its Q2 earnings this Tuesday after market hours. Analysts expect the company's revenue to grow by 24.3% year-on-year, improving from the previous year's 5.6% increase. Despite Supernus Pharmaceuticals beating revenue expectations last quarter, it significantly missed EPS estimates, and its stock is currently down 5.5% over the last month.
